Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share

Analysts forecast that Kala Pharmaceuticals Inc (NASDAQ:KALA) will announce earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kala Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.43). The business is expected to report its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.72) to ($1.95). For the next financial year, analysts expect that the business will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.19) to ($1.32). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Kala Pharmaceuticals.

KALA has been the topic of a number of research reports. BidaskClub upgraded shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 29th. Wedbush restated an “outperform” rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $35.00 target price on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. Wells Fargo & Co restated an “outperform” rating and set a $19.00 target price (down from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $35.80.

Kala Pharmaceuticals (NASDAQ KALA) opened at $12.47 on Monday. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a 52-week low of $11.81 and a 52-week high of $26.75. The stock has a market cap of $302.11 and a PE ratio of -6.85.

In other news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The shares were acquired at an average cost of $12.83 per share, for a total transaction of $2,185,436.54. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders purchased a total of 1,083,150 shares of company stock worth $15,449,144 over the last quarter.

Large investors have recently made changes to their positions in the stock. Orbimed Advisors LLC acquired a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $54,251,000. JPMorgan Chase & Co. acquired a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $4,037,000. Bank of New York Mellon Corp acquired a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $540,000. Crestline Management LP acquired a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $888,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $2,907,000. Institutional investors and hedge funds own 62.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/12/zacks-brokerages-expect-kala-pharmaceuticals-inc-kala-will-post-earnings-of-0-37-per-share.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply